

Partner, Washington, D.C.

Antitrust/Competition



T: 202.371.7146
julia.york@skadden.com

Education

J.D., Columbia University School of Law, 2001 (Harlan Fiske Stone Scholar)

B.A., Amherst College, 1997 (German Studies)

Bar Admissions

District of Columbia
Illinois

Languages

German

Julia York has represented numerous global corporations in various industries, including pharmaceuticals, telecommunications, energy and financial markets, in both litigation and transactional matters.

Selected experience includes defending or representing:

- Activision Blizzard, Inc. in a lawsuit brought by the Federal Trade Commission (FTC) challenging the proposed acquisition of the company by Microsoft
- Apple Inc. in two lawsuits brought by an advertiser purporting to represent a class and by a group of consumers, both alleging that Apple and Google engaged in a horizontal conspiracy not to compete in the “search business”
- Norfolk Southern Railway Co. in a federal antitrust case alleging that the company and three other major U.S. freight railroads conspired to charge supracompetitive fuel charges
- Sprint Corp. in a lawsuit brought by state attorneys general challenging the proposed acquisition of Sprint by T-Mobile
- Actavis, Inc. in a suit brought by the FTC, including before the U.S. Supreme Court, challenging the legality of a patent litigation settlement
- Actavis, Inc., Teva Pharmaceuticals USA, Inc. and a Teva Pharmaceuticals USA, Inc. affiliate in “reverse-payment” litigations related to the brand-name drug AndroGel 1%
- Medicis Pharmaceutical Corp. in multidistrict “reverse-payment” class action litigation related to the acne product Solodyn
- Johnson-Matthey in a suit brought by Actelion Pharmaceuticals Ltd. against multiple prospective generic manufacturers involving monopolization and restraint of trade claims in connection with Actelion’s REMS and restricted pharmaceutical distribution programs
- brand-name and generic pharmaceutical companies in connection with FTC investigations and inquiries
- a pharmaceutical company CEO in a challenge to an FTC investigation

Ms. York currently serves as the vice chair of the ABA Antitrust Section’s Antitrust Law Development Committee and regularly appears on discussion panels on antitrust issues relevant to the pharmaceutical industry. She actively works on *pro bono* matters, including representing various *amici curiae* on briefs submitted to the U.S. Supreme Court and U.S. Circuit Courts of Appeals. Ms. York has been named repeatedly as one of Lawdragon’s 500 Leading Litigators in America and 500 Leading Lawyers in America. She also has been recognized in *The Legal 500 U.S.*

Prior to joining Skadden, Ms. York counseled clients from diverse industries in connection with DOJ and FTC investigations into mergers and acquisitions. Other prior experience included representing a television industry client in a DOJ criminal price-fixing investigation, as well as representing a telecommunications industry client and an aluminum industry client in international arbitration proceedings in Switzerland.

Selected Publications

“DOJ and FTC Propose a New Playbook for Merger Reviews,” *Skadden, Arps, Slate, Meagher & Flom LLP*, July 19, 2023

“Skadden Discusses DOJ Loss in Fourth Criminal No-Poach Case,” *The CLS Blue Sky Blog*, May 9, 2023